[Corrected, 1/14/16, see below] This past week, the biopharma industry made its annual January pilgrimage to San Francisco for the J.P. Morgan Healthcare Conference. 2016 was a whirlwind year in biotech, and the biopharma gods rewarded attendees with a... Read more »
[Editor’s note: Ben Fidler contributed to this report] The week of frenetic data sharing, deal talking, and party hopping of the J.P. Morgan Healthcare Conference—and the events that have mushroomed around it—took a punch to the gut just as... Read more »
Manufacturing problems have held back several drugs from FDA approval, and the latest example is a Tesaro drug developed to ease nausea and vomiting in cancer patients.
Tesaro (NASDAQ: TSRO) said Thursday that the FDA raised no concerns about the... Read more »
Venture investments in Boston-area companies dipped in 2016, amid a slowdown in VC activity nationwide that some observers are calling a “return to normalization” after an investing frenzy in the previous two years.
In the fourth quarter of 2016, Boston-area companies... Read more »
A group of more than 100 prominent life sciences executives, investors, and business leaders have signed an open letter calling on the industry to step up efforts to increase gender diversity.
The letter was published Wednesday, on the second to... Read more »
Oh, the power of a Donald Trump sound bite. On the campaign trail and as president-elect he has made occasional noises about drug pricing—giving the U.S. Medicare system, the largest buyer of drugs in the world, the right to negotiate prices,... Read more »
Vertex Pharmaceuticals is unloading a group of ancillary research programs in its portfolio, announcing today it will out-license the potential cancer treatments to Darmstadt, Germany-based Merck KGaA.
Merck KGaA is paying Boston-based Vertex $230 million up front for the drug candidates,... Read more »
Takeda Pharmaceutical, aiming to bolster its cancer drug pipeline, has signed on Maverick Therapeutics to a $125 million partnership for developing new immunotherapy treatments.
The funding for Brisbane, CA-based Maverick includes an upfront option, a $23 million Series B investment, and... Read more »
[Updated 1/11/17, 11:46 a.m. See below.] Boston online food-ordering company ezCater has hauled in another big venture capital round.
Today the company announced a $35 million investment led by new backer Iconiq Capital; Insight Venture Partners, a previous ezCater... Read more »
While we’re looking at venture deal numbers from the past year, let’s consider the education technology industry, which isn’t broken out by sector in the general reports I’ve seen.
A recent study by EdSurge, an edtech information firm, shows... Read more »
The first test of pharmaceutical giant Allergan’s promise to behave responsibly came last week. The firm acknowledged price hikes on several drugs that stayed—sometimes barely—under the 10 percent limit that CEO Brent Saunders pledged last September, in what he called a... Read more »
Apperian, one of the early companies to build mobile applications for large enterprises, has been acquired by app-security firm Arxan.
The purchase price wasn’t disclosed, so it’s hard to tell how good an outcome this is for Apperian and its investors.... Read more »
Venture capital firms didn’t exactly take their foot off the accelerator, but the pace of VC investments continued to weaken in the three months that ended in December, extending a slowdown that began in July, according to two venture reports issued... Read more »